首页> 美国卫生研究院文献>Springer Open Choice >Newborn Screening for Primary Immunodeficiency Diseases: History Current and Future Practice
【2h】

Newborn Screening for Primary Immunodeficiency Diseases: History Current and Future Practice

机译:原发性免疫缺陷疾病的新生儿筛查:历史当前和将来的实践

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The primary objective of population-based newborn screening is the early identification of asymptomatic infants with a range of severe diseases, for which effective treatment is available and where early diagnosis and intervention prevent serious sequelae. Primary immunodeficiency diseases (PID) are a heterogeneous group of inborn errors of immunity. Severe combined immunodeficiency (SCID) is one form of PID which is uniformly fatal without early, definitive therapy, and outcomes are significantly improved if infants are diagnosed and treated within the first few months of life. Screening for SCID using T cell receptor excision circle (TREC) analysis has been introduced in many countries worldwide. The utility of additional screening with kappa recombining excision circles (KREC) has also been described, enabling identification of infants with severe forms of PID manifested by T and B cell lymphopenia. Here, we review the early origins of newborn screening and the evolution of screening methodologies. We discuss current strategies employed in newborn screening programs for PID, including TREC and TREC/KREC-based screening, and consider the potential future role of protein-based assays, targeted sequencing, and next generation sequencing (NGS) technologies, including whole genome sequencing (WGS).
机译:基于人群的新生儿筛查的主要目标是及早发现具有多种严重疾病的无症状婴儿,对其进行有效治疗以及早期诊断和干预可预防严重后遗症。原发性免疫缺陷疾病(PID)是先天性免疫错误的异质性组。严重的联合免疫缺陷病(SCID)是PID的一种形式,如果不进行早期明确的治疗,则是致命的,如果在出生后的头几个月内对婴儿进行诊断和治疗,结局将得到显着改善。使用T细胞受体切除环(TREC)分析筛查SCID已在全球许多国家/地区引入。还描述了用κ重组切除环(KREC)进行额外筛查的实用性,从而能够鉴定出由T细胞和B细胞淋巴细胞减少所表现出的严重PID形式的婴儿。在这里,我们回顾了新生儿筛查的早期起源以及筛查方法的演变。我们讨论了目前用于PID新生儿筛查计划的策略,包括基于TREC和TREC / KREC的筛查,并考虑了基于蛋白质的检测,靶向测序和下一代测序(NGS)技术(包括全基因组测序)的潜在未来作用(WGS)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号